KANBO Biotech 2025 Q4 Financials
NQ Score
58/100
N1 Content Completeness
7
AI Summary (NQ-processed)
KANBO Biotech (6919), a biotechnology and medical care company, reported a basic EPS of -0.23 NTD for Q4 2025, with operating revenue of 0.038 billion NTD and a net loss of 0.352 billion NTD after tax.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: 康霈生技在2025年第四季的獲利狀況如何？
- A: 該公司在2025年第四季稅後淨利為-3.52億元，基本每股盈餘為-0.23元。
- Q: What was Kang Pei Biotech's profitability in Q4 2025?
- A: In the fourth quarter of 2025, the company reported a net profit after tax of -3.52 billion yuan and basic earnings per share of -0.23 yuan.
- Q: 康霈生技の2025年第4四半期の収益状況はどうでしたか？
- A: 同社は2025年第4四半期に、税引後純利益-3.52億元、1株当たり純利益（EPS）-0.23元を記録しました。